Search company, investor...

R2 Technology

Founded Year



Acquired | Acquired

Total Raised




About R2 Technology

R2 Technology offers the the R2 ImageChecker system which was a CAD system approved by the U.S. Food and Drug Administration (FDA) for use with film-based mammography in 1998 and for digital mammography in 2001. R2 has received multiple supplemental approvals for technological and clinical advances and owns or has exclusive worldwide rights in more than 120 issued and pending patents. The ImageChecker CT Lung CAD system assists in the review of multi-slice CT chest exams to help maximize physician accuracy and efficiency in detecting actionable lung nodules as early as possible and tracking their size changes over time while helping detect filling defects such as pulmonary artery emboli.

Headquarters Location

2585 Augustine Drive 2585 Augustine Drive

Santa Clara, California, 95054,

United States


Missing: R2 Technology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: R2 Technology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest R2 Technology News

Hologic Acquires R2 Technology, Inc. - Jul 13, 2006

May 16, 2016

Hologic Acquires R2 Technology, Inc. A Leader in Computer Aided Detection (CAD) PRNewswire-FirstCall BEDFORD, Mass. BEDFORD, Mass., Jul. 13, 2006 / PRNewswire-FirstCall / -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, today announced it has completed the acquisition of R2 Technology, Inc., a global leader in computer aided detection (CAD). "This acquisition marks an important step forward in our strategy and efforts to grow our mammography business segment and expand our market share in women's health," said Jack Cumming, Chairman and Chief Executive Officer. "Our relationship with R2 is about working together, as respected industry leaders, in innovative ways to assist physicians in the early detection of breast cancer and lung disease. Combined, our customers have our assurance we will put our full resources behind development of new leading edge technologies to improve the spectrum of detection capabilities. We look forward to the opportunities that will develop from this combination as we continue to build value for our shareholders. " R2 Technology, Inc., located in Sunnyvale, California, is a recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists radiologists in the early detection of breast cancer. R2 Technology pioneered the use of CAD for mammography in 1998 when the ImageChecker system became the first CAD system approved by the FDA for screening mammography. The ImageChecker CAD system was also the first system approved for use with digital mammography. Under the terms of the agreement signed April 24, 2006, the purchase price for the transaction is approximately $220 million payable in approximately 4,630,300 shares of common stock. The actual number of shares of common stock that Hologic will issue in the transaction will be subject to reduction to reflect certain tax withholding obligations. Additionally, approximately 10% of the shares to be issued will be held in escrow and subject to forfeiture to satisfy R2 stockholder indemnification obligations, if any. "We are pleased we have finalized this agreement with Hologic," said John Pavlidis, President and CEO of R2 Technology, Inc. "We believe Hologic's experience and ability to work with partners to drive the adoption of value-added products in the sales channel will serve as the perfect complement to our technology platform. " About Hologic Hologic, Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to-digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit . About R2 Technology R2 Technology, Inc., headquartered in Sunnyvale, Calif., is a recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer, actionable lung nodules and other lung abnormalities. As a medical imaging company dedicated to diagnostic decision support, increasing physician productivity and preventing medical errors, R2 Technology is developing CAD systems for a variety of imaging modalities and disease states. For information, visit . Forward Looking Disclaimer This News Release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated benefits of Hologic's acquisition of R2. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks and uncertainties that may cause these forward-looking statements to vary materially from Hologic's expectations, include, among others: problems may arise with the ability of Hologic to successfully integrate the businesses of R2, which may result in the combined company not operating as effectively and efficiently as expected; Hologic may not be able to achieve the expected synergies from the acquisition or it may take longer than expected to achieve those synergies; the acquisition may involve unexpected costs or unexpected liabilities, or the effects of purchase accounting, may be different from Hologic's expectations; and the combined company may be adversely affected by future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors. Other factors that could materially adversely affect the business of Hologic include, without limitation, risks that may limit the Hologic's ability to increase commercial production of the Selenia and other of the Hologic's digital products, including Hologic's reliance on a single source of supply for some key components of its products as well as the need to comply with especially high standards for those components and in the manufacture of digital X-ray products in general; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the ability of the Hologic's sales force to successfully service its product offerings; Hologic's ability to successfully manage current or future acquisitions, alliances or joint ventures, including its recently acquired international operations; Hologic's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for digital X-ray products; expenses and uncertainties relating to litigation and governmental investigations, including the FTC's current investigation of Hologic's acquisition of certain intellectual property assets from Fischer Imaging, the proposed settlement of which is subject to FTC approval; risks relating to compliance with financial covenants under Hologic's leases; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based. Contact: Glenn P. Muir Frances Crecco Executive Vice President & CFO Director, Investor Relations Hologic, Inc. Hologic, Inc. (781) 999-7300 (781) 999-7377 SOURCE: Hologic, Inc. CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300, or Frances Crecco, Director, Investor Relations, +1-781-999-7377, both of Hologic, Inc.

R2 Technology Frequently Asked Questions (FAQ)

  • When was R2 Technology founded?

    R2 Technology was founded in 1993.

  • Where is R2 Technology's headquarters?

    R2 Technology's headquarters is located at 2585 Augustine Drive, Santa Clara.

  • What is R2 Technology's latest funding round?

    R2 Technology's latest funding round is Acquired.

  • How much did R2 Technology raise?

    R2 Technology raised a total of $71.31M.

  • Who are the investors of R2 Technology?

    Investors of R2 Technology include Hologic, Morgan Stanley, Sigma Partners, ARCH Venture Partners, GE Capital and 23 more.

  • Who are R2 Technology's competitors?

    Competitors of R2 Technology include Integrated Nano-Technologies, Median Technologies, Novasom, Infrascan, Advanced Cell Diagnostics and 11 more.

Compare R2 Technology to Competitors


QuantomiX develops products for rapid, high resolution imaging of wet samples.The company was founded in 2001 to commercialize its technology which, for a time, aims to enable direct imaging of fully hydrated samples in an electron microscope.With the Quantomix QXTM capsule product line, wet samples, including cells and tissues, can now be examined without any of the conventional treatments such as drying, deep freezing and sectioning. This opens the way to a better understanding of biomedical processes, to improved patient care, and to more effective pharmaceutical research.The QXTM capsules, that fit any Scanning Electron Microscope (SEM), close the resolution gap between conventional electron microscopy and light microscopy. They offer the convenient sample preparation of light microscopy.

Neuro Diagnostic Devices

NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.

MEC Dynamics

MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.

m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

Huron Digital Pathology

Huron Digital Pathology, previously known as Biomedical Photometric, aims to provide panoramic confocal scanning laser microscopes for the pathology, medical research, genomics, and general microscopy markets. The company was founded in 1994 and is based in Waterloo, Canada.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.